Module

The Next Generation of NNRTIs

Source: The Clinical Impact of Next-Generation NNRTIs: Recent Research and Practical Treatment Strategies

The Next Generation of NNRTIs

Faculty:

Anton L. Pozniak, MD, FRCP

CME CREDIT INFORMATION

Release Date: 09/14/07

Expiration Date: 09/13/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Identify the strengths and limitations of the first-generation NNRTIs
Discuss data from randomized clinical trials investigating next-generation NNRTIs
Describe next-generation NNRTIs in early clinical and preclinical development

Topics covered include:

Do We Need Next-Generation NNRTIs?
The First-Generation NNRTIs: Efficacy
The First-Generation NNRTIs: Toxicity
The First-Generation NNRTIs: Resistance
The First-Generation NNRTIs: Effect of Primary Resistance
The First-Generation NNRTIs: Adherence and Resistance Mutations
The Next-Generation NNRTIs
The Next-Generation NNRTIs: Etravirine (TMC125)
The Next-Generation NNRTIs: Rilpivirine (TMC278)
Other Next-Generation NNRTIs in Clinical and Preclinical Development
Implications of Next-Generation NNRTIs on Clinical Practice
Summary and Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.